Using gold nanoparticles to enhance cancer treatment with radiation
Rational translation of gold nanoparticle mediated radiosensitization to the clinic
This study is looking at how tiny gold particles can help make radiation therapy work better for cancer by making sure they get to the tumor more effectively, which could lead to better treatment outcomes for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Sci Ctr Houston NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11055388 on NIH RePORTER |
What this research studies
This research investigates how gold nanoparticles can improve the effectiveness of radiation therapy for tumors. By focusing on a method called 'active targeting,' the study aims to ensure that these nanoparticles are delivered more effectively to cancer cells, potentially increasing the radiation dose that tumors receive. The research will explore how these nanoparticles behave in the body, how they accumulate in tumors, and how they can enhance the effects of radiation therapy. The goal is to overcome existing challenges and prepare for clinical applications that could benefit patients undergoing cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research would be patients with tumors that are being treated with radiation therapy.
Not a fit: Patients who are not undergoing radiation therapy or do not have tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that improve patient outcomes and reduce side effects.
How similar studies have performed: Previous research has shown promising results with gold nanoparticles in enhancing radiation therapy, but this specific approach is still being developed and tested.
Where this research is happening
Houston, United States
- University of Texas Hlth Sci Ctr Houston — Houston, United States (Active)
Researchers
- Principal investigator: Krishnan, Sunil — University of Texas Hlth Sci Ctr Houston
- Study coordinator: Krishnan, Sunil
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.